WP Advisors LLC purchased a new position in shares of Eli Lilly And Co (NYSE:LLY) during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 296 shares of the company’s stock, valued at approximately $38,000.
Several other hedge funds and other institutional investors have also recently bought and sold shares of LLY. Oregon Public Employees Retirement Fund raised its stake in shares of Eli Lilly And Co by 17,720.8% during the fourth quarter. Oregon Public Employees Retirement Fund now owns 42,420,406 shares of the company’s stock valued at $367,000 after acquiring an additional 42,182,367 shares during the last quarter. Norges Bank acquired a new stake in shares of Eli Lilly And Co during the fourth quarter worth $1,056,086,000. FMR LLC grew its holdings in Eli Lilly And Co by 83.9% in the fourth quarter. FMR LLC now owns 13,687,081 shares of the company’s stock worth $1,583,870,000 after purchasing an additional 6,242,865 shares during the period. Amundi Pioneer Asset Management Inc. grew its holdings in Eli Lilly And Co by 165.4% in the fourth quarter. Amundi Pioneer Asset Management Inc. now owns 6,012,822 shares of the company’s stock worth $695,804,000 after purchasing an additional 3,747,482 shares during the period. Finally, BlackRock Inc. grew its holdings in Eli Lilly And Co by 3.0% in the fourth quarter. BlackRock Inc. now owns 68,956,519 shares of the company’s stock worth $7,979,649,000 after purchasing an additional 2,030,845 shares during the period. Institutional investors and hedge funds own 79.58% of the company’s stock.
In other Eli Lilly And Co news, major shareholder Lilly Endowment Inc sold 205,000 shares of Eli Lilly And Co stock in a transaction dated Tuesday, February 19th. The shares were sold at an average price of $122.48, for a total value of $25,108,400.00. Following the sale, the insider now owns 117,641,684 shares of the company’s stock, valued at $14,408,753,456.32. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Melissa S. Barnes sold 4,735 shares of Eli Lilly And Co stock in a transaction dated Friday, April 12th. The stock was sold at an average price of $125.15, for a total transaction of $592,585.25. Following the completion of the sale, the insider now directly owns 22,085 shares in the company, valued at approximately $2,763,937.75. The disclosure for this sale can be found here. Insiders have sold 1,003,959 shares of company stock worth $125,426,338 over the last three months. 0.11% of the stock is owned by insiders.
LLY opened at $119.96 on Wednesday. The company has a debt-to-equity ratio of 1.07, a quick ratio of 1.38 and a current ratio of 1.73. Eli Lilly And Co has a fifty-two week low of $77.09 and a fifty-two week high of $132.13. The stock has a market cap of $128.52 billion, a P/E ratio of 21.61, a PEG ratio of 2.35 and a beta of 0.33.
Eli Lilly And Co (NYSE:LLY) last released its quarterly earnings results on Wednesday, February 6th. The company reported $1.33 earnings per share for the quarter, missing analysts’ consensus estimates of $1.36 by ($0.03). Eli Lilly And Co had a net margin of 13.16% and a return on equity of 44.66%. The firm had revenue of $6.44 billion for the quarter, compared to the consensus estimate of $6.28 billion. During the same period in the previous year, the business earned $1.14 earnings per share. The firm’s revenue for the quarter was up 4.5% on a year-over-year basis. Equities research analysts predict that Eli Lilly And Co will post 5.66 EPS for the current fiscal year.
A number of equities research analysts have commented on LLY shares. Zacks Investment Research cut shares of Eli Lilly And Co from a “buy” rating to a “hold” rating in a report on Tuesday, December 18th. BMO Capital Markets restated a “buy” rating on shares of Eli Lilly And Co in a report on Wednesday, December 19th. Morgan Stanley set a $116.00 price target on shares of Eli Lilly And Co and gave the stock a “hold” rating in a report on Thursday, December 20th. Argus restated a “buy” rating on shares of Eli Lilly And Co in a report on Thursday, December 27th. Finally, Barclays restated a “buy” rating and issued a $130.00 price target on shares of Eli Lilly And Co in a report on Sunday, January 20th. Ten analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $118.02.
Eli Lilly And Co Profile
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.
Further Reading: Why Dividend Stocks May Be Right for You
Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.